{
  "resourceType" : "CodeSystem",
  "id" : "ATCMixedCodes",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem ATCMixedCodes</b></p><a name=\"ATCMixedCodes\"> </a><a name=\"hcATCMixedCodes\"> </a><a name=\"ATCMixedCodes-en-US\"> </a><p>This case-sensitive code system <code>https://kip.rkkp.dk/fhir/CodeSystem/ATCMixedCodes</code> defines the following codes in an undefined hierarchy:</p><table class=\"codes\"><tr><td><b>Lvl</b></td><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td>1</td><td style=\"white-space:nowrap\">tki<a name=\"ATCMixedCodes-tki\"> </a></td><td>TKI (Tyrosine kinase inhibitors)</td><td>TKI (Tyrosine kinase inhibitors)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0L01EA<a name=\"ATCMixedCodes-L01EA\"> </a></td><td>BCR-ABL tyrosine kinase inhibitors</td><td/></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0L01EB<a name=\"ATCMixedCodes-L01EB\"> </a></td><td>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors</td><td/></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0L01EH<a name=\"ATCMixedCodes-L01EH\"> </a></td><td>Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors</td><td/></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0L01EK<a name=\"ATCMixedCodes-L01EK\"> </a></td><td>Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors</td><td/></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0L01EN<a name=\"ATCMixedCodes-L01EN\"> </a></td><td>Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors</td><td/></tr></table></div>"
  },
  "url" : "https://kip.rkkp.dk/fhir/CodeSystem/ATCMixedCodes",
  "version" : "0.2.1",
  "name" : "ATCMixedCodes",
  "title" : "WHO ATC; Mixed codes",
  "status" : "active",
  "date" : "2022-07-14T00:00:00+02:00",
  "publisher" : "Sundhedsvæsnets Kvalistetsinstitut with Trifork Digital Health A/S",
  "contact" : [{
    "name" : "Sundhedsvæsnets Kvalistetsinstitut with Trifork Digital Health A/S",
    "telecom" : [{
      "system" : "url",
      "value" : "https://trifork.com"
    },
    {
      "system" : "email",
      "value" : "rbk@trifork.com"
    }]
  }],
  "description" : "WHO ATC code system; Mixed codes. Link: http://www.whocc.no/atc",
  "caseSensitive" : true,
  "content" : "complete",
  "count" : 6,
  "concept" : [{
    "code" : "tki",
    "display" : "TKI (Tyrosine kinase inhibitors)",
    "definition" : "TKI (Tyrosine kinase inhibitors)",
    "concept" : [{
      "code" : "L01EA",
      "display" : "BCR-ABL tyrosine kinase inhibitors"
    },
    {
      "code" : "L01EB",
      "display" : "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors"
    },
    {
      "code" : "L01EH",
      "display" : "Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors"
    },
    {
      "code" : "L01EK",
      "display" : "Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors"
    },
    {
      "code" : "L01EN",
      "display" : "Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors"
    }]
  }]
}